Overcoming Innate Immune Barriers that Impede AAV Gene Therapy Vectors
Time: 3:30 pm
day: Day Two
Details:
- What is known about innate immune responses in AAV-based gene therapy?
- Understand the role of complement in AAV immunogenicity
- Potential immunomodulatory strategies to circumvent AAV related immune responses
- Despite the recent clinical successes achieved with AAVs for therapeutics, host innate immune responses against the vector and transgene product have been observed in numerous preclinical and clinical studies
- These outcomes have hampered the advancement of AAV gene therapies, preventing them from becoming fully viable and safe medicines
- Assess the role of the innate immune system on the vector and its role in priming the adaptive immune system to attack said vector
